Latest Property Portfolio News

Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.

Temas Resources has filed a new patent for its proprietary Regenerative Chloride Leach (RCL) process targeting vanadium extraction, broadening its critical minerals technology portfolio and reinforcing its commercial licensing ambitions.

ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.

Botanix Pharmaceuticals has received an Intention to Grant from the European Patent Office for a patent protecting its Sofdra applicator technology, potentially extending exclusivity in Europe until 2039.

Booster Wines Limited has proposed exiting its Hawke’s Bay vineyard and winery leases from the Private Land and Property Portfolio, offering a discounted convertible debt payment amid falling grape demand.

Foresta Group Holdings has received allowance from the USPTO for its US patent application covering its proprietary rosin and terpene production process, expected to protect its technology until at least 2041.

Dexus's latest external valuations reveal a modest 0.2% decline in its stabilised office and industrial portfolio values as of June 2026, reflecting subtle shifts in capitalisation rates and rental growth.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

Booster Investment Scheme 2's Private Land and Property Fund swung back to profit with NZD 1.3 million after tax for the year ended March 2026, despite net asset value slipping due to unit redemptions. The Fund’s investment portfolio remains concentrated in unlisted New Zealand agricultural and property assets, while its Manager faces unrelated FMA proceedings.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.